ReviewDiabetes therapy : research, treatment and education of diabetes and related disorders2018
Safety and Efficacy of DPP4 Inhibitor and Basal Insulin in Type 2 Diabetes: An Updated Review and Challenging Clinical Scenarios.
Review in Diabetes therapy : research, treatment and education of diabetes and related disorders, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 2 syntheses or guidelines pooled it, 58 citations in OpenAlex.
- A Critical View over the Newest Antidiabetic Molecules in Light of Efficacy-A Systematic Review and Meta-Analysis.International journal of molecular sciences · 2023Pooled it
- DPP-4 inhibitors may improve the mortality of coronavirus disease 2019: A meta-analysis.PloS one · 2021Pooled it
- Comparative Analysis of Potential Side Effects of Targeted Oral Hypoglycemic Agents Using Spontaneous Adverse Event Reports and Social Media Data.Pharmacoepidemiology and drug safety · 2026Article
- Pharmacogenomic study of the effects of saxagliptin on glucose control and hypoglycemic events.BMC medical genomics · 2026Article
- EffiCacy and safety of ANagliptin when added to iNsulin and metformin therapy in patients with uncontrolled type 2 diAbetes; randomized, placebo-controlled, double-blind, multicentre trial (CANNA study).Diabetes, obesity & metabolism · 2025Article
- Cluster Analysis in Diabetes Research: A Systematic Review Enhanced by a Cross-Sectional Study.Journal of clinical medicine · 2025Review
- Expert eValuation of Efficacy and Rationality of Vildagliptin "EVER-Vilda": An Indian Perspective.Clinical medicine insights. Endocrinology and diabetes · 2024Article
- Article
- Role of diet and exercise in aging, Alzheimer's disease, and other chronic diseases.Ageing research reviews · 2023Review
- Incident infection risks depending on oral antidiabetic exposure in insulin-treated type 2 diabetes patients.Scientific reports · 2023Article
- A Review of Hyperglycemia in COVID-19.Cureus · 2023Review
- Effect of a combination of gliptin and metformin on serum vitamin B12, folic acid, and ferritin levels.Revista da Associacao Medica Brasileira (1992) · 2023Article
- Investigation of Alogliptin-Loaded In Situ Gel Implants by 2Pharmaceutics · 2022Article
- Bullous pemphigoid in diabetic patients treated by gliptins: the other side of the coin.Journal of translational medicine · 2021Review
- Importance of hyperglycemia in COVID-19 intensive-care patients: Mechanism and treatment strategy.Primary care diabetes · 2021Review
- The therapeutic effects of berberine plus sitagliptin in a rat model of fatty liver disease.Iranian journal of basic medical sciences · 2021Article
- Diabetes in People with HIV.Current diabetes reports · 2021Review
- Clinical Characteristics and Risk of Diabetic Complications in Data-Driven Clusters Among Type 2 Diabetes.Frontiers in endocrinology · 2021Article
- Prevention and management of COVID-19 among patients with diabetes: an appraisal of the literature.Diabetologia · 2020Review
- Aberrant expression of miR-214 is associated with obesity-induced insulin resistance as a biomarker and therapeutic.Diagnostic pathology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 2 countries.
Funding
Abstract
The safety and efficacy of dipeptidyl peptidase-4 (DPP4) inhibitors as monotherapy or in combination with other oral antidiabetic agents or basal insulin are well established. DPP4 inhibitors stimulate glucose-dependent insulin secretion and inhibit glucagon production. As monotherapy, they reduce the hemoglobin A1c level by about 0.6-0.8%. The addition of a DPP4 inhibitor to basal insulin is an attractive option, because they lower both postprandial and fasting plasma glucose concentrations without increasing the risk of hypoglycemia or weight gain. The present review summarizes the extensive evidence on the combination therapy of DPP4 inhibitors and insulin-based regimens in patients with type 2 diabetes. We focus our discussion on challenging clinical scenarios including patients with chronic renal impairment, elderly persons and hospitalized patients. The evidence indicates that these drugs are highly effective and safe in the elderly and in the presence of mild, moderate and severe renal failure improving glycemic control with low risk of hypoglycemia. In addition, several randomized-controlled trials have shown that the use of DPP4 inhibitors in combination with basal insulin represents an alternative to the basal-bolus insulin regimen in hospitalized patients with type 2 diabetes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.